Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2026
This study aims to compare the efficacy and safety of a shortened treatment course based on the bone marrow blast count on Day 14 versus standard treatment in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
Epistemonikos ID: a3c53a0f92567b8f710516fdc830ba07017245fe
First added on: Feb 13, 2026